Cargando…

Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy

Disruption of the complement regulatory system can provoke thrombotic microangiopathy (TMA), leading to clinical manifestations of generalized fatigue from hemolytic anemia, purpura caused by thrombocytopenia, and acute kidney injury from end-organ ischemia. This particular classification of TMA is...

Descripción completa

Detalles Bibliográficos
Autores principales: Livingston, Jonathan, Dhanesar, Gurneel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148266/
https://www.ncbi.nlm.nih.gov/pubmed/37128526
http://dx.doi.org/10.7759/cureus.36896
_version_ 1785034962020335616
author Livingston, Jonathan
Dhanesar, Gurneel
author_facet Livingston, Jonathan
Dhanesar, Gurneel
author_sort Livingston, Jonathan
collection PubMed
description Disruption of the complement regulatory system can provoke thrombotic microangiopathy (TMA), leading to clinical manifestations of generalized fatigue from hemolytic anemia, purpura caused by thrombocytopenia, and acute kidney injury from end-organ ischemia. This particular classification of TMA is known as complement-mediated thrombotic microangiopathy (CM-TMA). In CM-TMA, an inciting event such as infection, surgery, vaccination, or pregnancy triggers an inflammatory response resulting in the expression of inherited mutations or the development of autoantibodies against complement regulatory proteins, which leads to microangiopathic hemolytic anemia, thrombocytopenia, and direct damage to renal endothelial cells. The diverse etiologies of CM-TMA make diagnostic and therapeutic decisions a challenging endeavor. We encountered a young male patient who presented with significant lethargy and confusion. The initial diagnosis was consistent with systemic inflammatory response syndrome secondary to acute pancreatitis; however, the hospital course was complicated by subsequent acute renal failure, hemolytic anemia, and thrombocytopenia, likely indicating CM-TMA. The patient was successfully treated with plasma exchange therapy and eculizumab. We suspect that our patient likely developed CM-TMA from an episode of acute pancreatitis. Prompt diagnosis and early intervention are essential to improving morbidity and mortality. This is underscored by the development of monoclonal antibody therapy that directly targets the pathogenic complement proteins, which have been shown to improve renal disease outcomes.
format Online
Article
Text
id pubmed-10148266
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101482662023-04-30 Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy Livingston, Jonathan Dhanesar, Gurneel Cureus Internal Medicine Disruption of the complement regulatory system can provoke thrombotic microangiopathy (TMA), leading to clinical manifestations of generalized fatigue from hemolytic anemia, purpura caused by thrombocytopenia, and acute kidney injury from end-organ ischemia. This particular classification of TMA is known as complement-mediated thrombotic microangiopathy (CM-TMA). In CM-TMA, an inciting event such as infection, surgery, vaccination, or pregnancy triggers an inflammatory response resulting in the expression of inherited mutations or the development of autoantibodies against complement regulatory proteins, which leads to microangiopathic hemolytic anemia, thrombocytopenia, and direct damage to renal endothelial cells. The diverse etiologies of CM-TMA make diagnostic and therapeutic decisions a challenging endeavor. We encountered a young male patient who presented with significant lethargy and confusion. The initial diagnosis was consistent with systemic inflammatory response syndrome secondary to acute pancreatitis; however, the hospital course was complicated by subsequent acute renal failure, hemolytic anemia, and thrombocytopenia, likely indicating CM-TMA. The patient was successfully treated with plasma exchange therapy and eculizumab. We suspect that our patient likely developed CM-TMA from an episode of acute pancreatitis. Prompt diagnosis and early intervention are essential to improving morbidity and mortality. This is underscored by the development of monoclonal antibody therapy that directly targets the pathogenic complement proteins, which have been shown to improve renal disease outcomes. Cureus 2023-03-30 /pmc/articles/PMC10148266/ /pubmed/37128526 http://dx.doi.org/10.7759/cureus.36896 Text en Copyright © 2023, Livingston et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Livingston, Jonathan
Dhanesar, Gurneel
Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy
title Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy
title_full Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy
title_fullStr Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy
title_full_unstemmed Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy
title_short Acute Pancreatitis: A Rare Cause of Complement-Mediated Thrombotic Microangiopathy
title_sort acute pancreatitis: a rare cause of complement-mediated thrombotic microangiopathy
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148266/
https://www.ncbi.nlm.nih.gov/pubmed/37128526
http://dx.doi.org/10.7759/cureus.36896
work_keys_str_mv AT livingstonjonathan acutepancreatitisararecauseofcomplementmediatedthromboticmicroangiopathy
AT dhanesargurneel acutepancreatitisararecauseofcomplementmediatedthromboticmicroangiopathy